PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.10%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
-94.58%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-14.44%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-14.44%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
4.10%
Interest expense growth 0-5% reflects moderate increase. Benjamin Graham would check leverage ratios.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBITDA growth 12-15% shows strong operational improvement. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
14.44%
Operating income growth 12-15% shows strong operational performance. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.51%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
12.51%
Net income growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
12.37%
EPS growth 12-15% shows strong earnings momentum. Peter Lynch would examine growth drivers.
12.37%
Diluted EPS growth 12-15% shows strong earnings power. Peter Lynch would examine growth drivers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.